Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Company Deals

Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million

Fineline Cube Jul 8, 2026
Company Deals

MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001

Fineline Cube Jul 8, 2026
Company Deals

Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China

Fineline Cube Jul 8, 2026
Policy / Regulatory

China Adds Methoxyethyl Etomidate, Loretomidate and Solriamfetol to Controlled Psychotropic Substances List

Fineline Cube Jul 8, 2026
Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline

Fineline Cube Jul 8, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Fineline Cube Jul 8, 2026
Company Drug

Eli Lilly’s Tirzepatide Earns China Approval for Type 2 Diabetes Treatment

Fineline Cube May 21, 2024

Eli Lilly & Co. (NYSE: LLY), a leading US pharmaceutical company, has announced that it...

Company Deals

Blue Sail Medical Subsidiary Secures RMB 100 Million Investment to Expand Operations

Fineline Cube May 21, 2024

China’s Blue Sail Medical Co., Ltd (SHE: 002382) has announced that Blue Sail Biosensors Medical...

Company Deals

Jiayue Pharmaceutical’s JYP0015 Secures $365 Million Licensing Agreement with Erasca

Fineline Cube May 21, 2024

Guangzhou Jiayue Pharmaceutical Technology Co., Ltd, a Chinese pharmaceutical company, has entered into a licensing...

Policy / Regulatory

China’s CDE Reports Record High in Clinical Trials for Innovative Drugs in 2023

Fineline Cube May 21, 2024

The Center for Drug Evaluation (CDE) has released its annual report, highlighting the growth in...

Company Drug

Gilead’s Seladelpar Shows Interim Benefits in PBC-Related Itch Clinical Trial

Fineline Cube May 21, 2024

Gilead Sciences (NASDAQ: GILD) has announced interim results from a long-term study assessing the safety...

Company

AstraZeneca Commits $1.5 Billion to Build Singapore-Based ADC Manufacturing Facility

Fineline Cube May 21, 2024

UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced plans for a $1.5 billion greenfield...

Policy / Regulatory

NHSA Unveils 2024 Medical Procurement Overhaul, Aiming for Synergy Between National and Provincial Levels

Fineline Cube May 21, 2024

The National Healthcare Security Administration (NHSA) has issued a notification detailing plans to enhance the...

Company Medical Device

BGI Genomics Delays Market Filing for BRCA1/2 Detection Kit Due to Incomplete Data

Fineline Cube May 21, 2024

BGI Genomics Co., Ltd (SHE: 300676), a leading genomics company based in China, has announced...

Company Medical Device

Hymson Laser’s Mid Infrared Femtosecond Laser Technology Makes Medical Industry Inroads

Fineline Cube May 21, 2024

Shenzhen-based Hymson Laser Technology Group Co., Ltd (SHA: 688559) has announced a significant breakthrough with...

Company Drug

BMS’s Sotyktu Sustains Clinical Response in Long-Term Psoriasis Treatment

Fineline Cube May 21, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) has announced the release of long-term clinical data for...

Policy / Regulatory

China and South Korea Reinforce Ties with Renewed MOU on Pharmaceuticals and Cosmetics Regulation

Fineline Cube May 21, 2024

The National Medical Products Administration (NMPA) of China and the Ministry of Food and Drug...

Company Deals

Pharmaron and AstraZeneca Enter Sweeping Partnership to Span Drug Development Services

Fineline Cube May 21, 2024

Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759;...

Company Drug

Jiangsu Hengrui’s SHR1905 Anti-TSLP mAb Gets Green Light for COPD Clinical Trial

Fineline Cube May 21, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent Chinese pharmaceutical company, announced that it...

Company Drug

Innovent Biologics’ IBI311 New Drug Application Accepted for Review by China’s CDE

Fineline Cube May 21, 2024

Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company in China, has announced that the...

Company Deals Digital Hospital

Union Hospital Teams Up with Baidu Health for AI-Enhanced Outpatient Services

Fineline Cube May 20, 2024

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, has entered into a...

Company Drug

Zai Lab and Innoviva Win China Approval for SUL-DUR to Treat Hospital-Acquired Pneumonia

Fineline Cube May 20, 2024

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a China-based biopharmaceutical company, in collaboration with US...

Company Drug

FDA Gives Accelerated Nod to Amgen’s Imdelltra in Small Cell Lung Cancer

Fineline Cube May 20, 2024

The US Food and Drug Administration (FDA) has granted accelerated approval to Amgen (NASDAQ: AMGN)...

Company Drug

Eli Lilly’s Weekly Insulin Efsitora Alfa Matches Daily Basal Insulins in Reducing A1C Levels

Fineline Cube May 20, 2024

Eli Lilly and Company (NYSE: LLY), a global healthcare company, has announced results from a...

Company Deals

Pharmaron to Sell Proteologix Stake in Upcoming Johnson & Johnson Acquisition

Fineline Cube May 20, 2024

Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759;...

Company Deals

Fosun Pharma Nods to Fosun Health Spin-Off; IPO Venue and Requirements Under Review

Fineline Cube May 20, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company in...

Posts pagination

1 … 384 385 386 … 692

Recent updates

  • Jenscare’s LuX-Valve Plus Secures CE Mark as World’s Second Transcatheter Tricuspid Valve Replacement
  • Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3/4 Inhibitor TQC3721
  • Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline
  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors
  • AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Jenscare’s LuX-Valve Plus Secures CE Mark as World’s Second Transcatheter Tricuspid Valve Replacement

Others

Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3/4 Inhibitor TQC3721

Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.